Aardvark Therapeutics, Inc. financial data

Symbol
AARD on Nasdaq
Location
4370 La Jolla Village Drive, Suite 1050, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.7M shares
Common Stock, Shares, Outstanding 21.7M shares
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 21.7M shares +447%
Weighted Average Number of Shares Outstanding, Diluted 21.7M shares +447%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.1M USD +226%
General and Administrative Expense 2.7M USD +33.2%
Operating Income (Loss) -15.8M USD -161%
Nonoperating Income (Expense) 1.48M USD +137%
Net Income (Loss) Attributable to Parent -14.4M USD -164%
Earnings Per Share, Basic -0.66 USD/shares +51.8%
Earnings Per Share, Diluted -0.66 USD/shares +51.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26M USD
Cash, Cash Equivalents, and Short-term Investments 142M USD
Assets, Current 145M USD
Operating Lease, Right-of-Use Asset 522K USD
Other Assets, Noncurrent 2.19M USD
Assets 147M USD
Accounts Payable, Current 5.06M USD
Employee-related Liabilities, Current 1.38M USD
Accrued Liabilities, Current 4.84M USD
Liabilities, Current 10.3M USD
Operating Lease, Liability, Noncurrent 228K USD
Other Liabilities, Noncurrent 12K USD
Liabilities 10.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -3K USD
Retained Earnings (Accumulated Deficit) -82M USD
Stockholders' Equity Attributable to Parent 137M USD
Liabilities and Equity 147M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD -420%
Net Cash Provided by (Used in) Financing Activities 88.9M USD
Net Cash Provided by (Used in) Investing Activities -113M USD -2252380%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 21.7M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26M USD -69.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -14.4M USD -165%
Operating Lease, Liability, Current 417K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5K USD +150%
Share-based Payment Arrangement, Expense 634K USD +1096%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares